ERBB2 and breast cancer: [14] established an RSF model based on real‐world single‐center data to predict prognosis for HER2‐low breast cancer patients, achieving AUC values of 0.726, 0.712, and 0.685 in the testing set, thereby providing clinicians with a valuable prognostic tool.